August 20, 2014

Who is the alternative analgesic pain consumer? “The majority of these people [in search of external pain relief] have chronic pain and are already taking prescriptions and using multiple methods of pain relief,” said Jenny McLaughlin, product manager for Walh Therapeutic Massagers. “Our research shows people are coming into the health-and-wellness area once a month.”

August 20, 2014

The entire external analgesic category is up 6.7%, reaching a base of $486.9 million across total U.S. multi-outlets for the 52 weeks ended June 15, according to IRI data. And Salonpas, with a 10.9% dollar share, is helping to drive that growth with positive sales gains of 28.7% to $52.9 million.

October 10, 2013

Hisamitsu America’s Salonpas has been experiencing significantgrowth in the past year with sales up 38% to $43.1 million.

July 30, 2013

Hisamitsu America, the manufacturer of Salonpas, an OTC pain patch that is FDA approved and clinically proven, announced the launch of Salonpas Deep Relieving Gel, a topical analgesic solution.

March 8, 2013

With private label across analgesics up an estimated 11.3% to $1.7 billion, retailers are going to need to make some tough decisions as two internal analgesic powerhouses — McNeil's Tylenol and Novartis' Excedrin — make their way back onto market after respective recalls.

January 25, 2011

Hisamitsu Pharmaceutical on Monday introduced the latest episode of its FauxObama online ad campaign promoting the company’s Salonpas pain patch products.